drugset / Trial / NCT05246618
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
Phase 1/2
Completed
18 enrolled
iCoat Medical AB
CTC Clinical Trial Consultants AB · collabRegion Skane · collab
RandomizedParallel-groupTriple-blindOther
Summary
A first-in-human single center, randomized, double-blind, placebo-controlled trial, with primary objective to evaluate safety and tolerability of ex-vivo kidney allograft treatment with TUM012 to reduce ischemia-reperfusion injury in de novo kidney transplant recipients.
Timeline
- Start
- 2022-03-31
- Primary completion
- 2023-07-31
- Completion
- 2024-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TUM012 | Unknown | — | Other |